R Squared’s Annovis Bio ANVS Stock Holding History

R Squared’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,520	Closed	-$7.65K	–	358
2024 Q4	$7.65K	Buy	+1,520	New	+$11K	0.01%	1223

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

GWM

Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

R Squared's ANVS Position: Q1 2025 in Review

R Squared sold out of Annovis Bio (ANVS) in Q1 2025, closing a stake of 1,520 shares — an estimated $7.65K sold.

R Squared first reported a position in ANVS in Q4 2024 and held it in 1 quarter. The position peaked at $7.65K in Q4 2024. 44 funds tracked by Wall St. Rank hold ANVS as of Q1 2025.

R Squared reported no remaining Annovis Bio position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,520 Annovis Bio shares in Q1 2025, an estimated $7.65K.
R Squared first reported a position in Annovis Bio in Q4 2024 and held it in 1 quarter.
R Squared's Annovis Bio position peaked at $7.65K in Q4 2024.
44 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.